Norma E. Farrow

Norma E. Farrow

Auto-generated profile, based on publicly available information

Norma E. Farrow

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VPVictor O. Popoola
Victor O. Popoola
BLBrandyn D. Lau
Brandyn D. Lau
HSHasan M. Shihab
Hasan M. Shihab
NFNorma E. Farrow
Norma E. Farrow
DSDauryne L. Shaffer
Dauryne L. Shaffer
EHElliott R. Haut
Elliott R. Haut
Venous thromboembolism (VTE) is a major cause of morbidity and mortality among hospitalized patients and is largely preventable. Strategies to decrease the burden of VTE have focused on improving clinicians’ prescribing of prophylaxis with relatively less emphasis on patient education. To develop a patient-centered approach to education of patients and their families on VTE: including importance, risk factors, and benefit/harm of VTE prophylaxis in hospital settings. The objective of this study was to develop a patient-centered approach to education of patients and their families on VTE: including importance, risk factors, and benefit/harm of VTE prophylaxis in hospital settings. We implemented a three-phase, web-based survey (SurveyMonkey) between March 2014 and September 2014 and analyzed survey data using descriptive statistics. Four hundred twenty one members of several national stakeholder organizations and a single local patient and family advisory board were invited to participate via email. We assessed participants’ preferences for VTE education topics and methods of delivery. Participants wanted to learn about VTE symptoms, risk factors, prevention, and complications in a context that emphasized harm. Although participants were willing to learn using a variety of methods, most preferred to receive education in the context of a doctor-patient encounter. The next most common preferences were for video and paper educational materials. Patients want to learn about the harm associated with VTE through a variety of methods. Efforts to improve VTE prophylaxis and decrease preventable harm from VTE should target the entire continuum of care and a variety of stakeholders including patients and their families.

2 November 2018 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
EHElliott R. Haut
Elliott R. Haut
JAJonathan K. Aboagye
Jonathan K. Aboagye
DSDauryne L. Shaffer
Dauryne L. Shaffer
JWJiangxia Wang
Jiangxia Wang
DHDeborah B. Hobson
Deborah B. Hobson
BLBrandyn D. Lau
Brandyn D. Lau
Venous thromboembolism (VTE) remains a leading cause of preventable morbidity and mortality among hospitalized patients1-4 and poses an immense economic burden.5,6 Numerous successful interventions have been implemented in hospitals around the world to improve prescription of appropriate VTE prophylaxis.7,8 However, a substantial proportion of prescribed VTE prophylaxis doses are not administered.9-14 The leading cause of nonadministration of VTE prophylaxis medication is patient refusal,9,10 the causes of which have been explored through quantitative and qualitative studies.15,16

1 April 2018 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
MTMegan C. Turner
Megan C. Turner
NFNorma E. Farrow
Norma E. Farrow
KRKristen E. Rhodin
Kristen E. Rhodin
ZSZhifei Sun
Zhifei Sun
MAMohamed A. Adam
Mohamed A. Adam
JMJohn Migaly
John Migaly
Adjuvant chemotherapy after resection is the standard of care for stage III colon cancer, yet many patients omit chemotherapy. We aimed to describe the impact of delayed chemotherapy on overall survival across multiple time points. The 2006 to 2014 National Cancer Data Base (NCDB) was queried for patients with single primary stage III adenocarcinoma of the colon. Patients were grouped by receipt and timing of chemotherapy from resection date: chemotherapy omitted, 24 weeks. Subgroup analyses were performed for those with comorbidities and those who had postoperative complications. Overall survival was compared using Cox proportional hazard modeling, adjusting for patient, tumor, and facility characteristics. In total, 72,057 patients were included; 20,807 omitted chemotherapy, 22,705 received it at 24 weeks after resection. Compared with patients who omitted chemotherapy, patients who received chemotherapy at 24 weeks (HR 0.68) had superior overall survival (p < 0.001). This survival benefit was preserved across subgroups (p < 0.001). After resection of stage III colon cancer, patients should receive adjuvant chemotherapy within 6 to 8 weeks for maximal benefit. However, chemotherapy should be offered to patients who are outside the optimal window, who have significant comorbidities, or who have had a complication more than 24 weeks from resection to improve the overall survival compared with omitting chemotherapy.

13 November 2019 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
NFNorma E. Farrow
Norma E. Farrow
SASelena J. An
Selena J. An
PSPaul J. Speicher
Paul J. Speicher
DHDavid H. Harpole
David H. Harpole
TDThomas A. D'AMico
Thomas A. D'AMico
BTBetty C. Tong
Betty C. Tong

25 March 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JMJohn T. Miura
John T. Miura
HKHidde M. Kroon
Hidde M. Kroon
GBGeorgia M. Beasley
Georgia M. Beasley
DMDean Mullen
Dean Mullen
NFNorma E. Farrow
Norma E. Farrow
JZJonathan S Zager
Jonathan S Zager

1 August 2017 in Journal of Critical Care
Verified
Journal Article
Closed access
DHDeborah B. Hobson
Deborah B. Hobson
TCTracy Y. Chang
Tracy Y. Chang
JAJonathan K. Aboagye
Jonathan K. Aboagye
BLBrandyn D. Lau
Brandyn D. Lau
HSHasan M. Shihab
Hasan M. Shihab
EHElliott R. Haut
Elliott R. Haut